ERBB2 and breast carcinoma: With the goal of expanding the repertoire of targets amenable for brain tumor CAR T cell therapy, this group is also evaluating HER2-targeted CAR T cells in the recurrent GBM setting (NCT03389230) as well as HER2 + breast cancer that has metastasized to the brain (NCT03696030).